These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35101281)

  • 21. Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study.
    Chen Z; Liu A; Cheng Y; Wang X; Xu X; Huang J; Ma Y; Gao M; Huang C
    BMC Infect Dis; 2021 Aug; 21(1):805. PubMed ID: 34384388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
    Vollaard A; Gieling EM; van der Linden PD; Sinha B; de Boer MGJ
    Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
    Derwand R; Scholz M
    Med Hypotheses; 2020 Sep; 142():109815. PubMed ID: 32408070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
    Pimentel J; Andersson N
    Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
    Garcia-Cremades M; Solans BP; Hughes E; Ernest JP; Wallender E; Aweeka F; Luetkemeyer AF; Savic RM
    Clin Pharmacol Ther; 2020 Aug; 108(2):253-263. PubMed ID: 32285930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
    Cui C; Tu S; En VSJ; Li X; Yao X; Li H; Liu D
    Curr Drug Metab; 2020; 21(6):427-435. PubMed ID: 32520683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.
    Pereira BB
    J Toxicol Environ Health B Crit Rev; 2020 May; 23(4):177-181. PubMed ID: 32281481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
    Naghipour S; Ghodousi M; Rahsepar S; Elyasi S
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1119-1133. PubMed ID: 32631083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis.
    Risch HA
    Am J Epidemiol; 2020 Nov; 189(11):1218-1226. PubMed ID: 32458969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opinion and uptake of chloroquine for treatment of COVID-19 during the mandatory lockdown in the sub-Saharan African region.
    Osuagwu UL; Nwaeze O; Ovenseri-Ogbomo G; Oloruntoba R; Ekpenyong B; Mashige KP; Timothy C; Ishaya T; Langsi R; Charwe D; Kwasi Abu E; Chundung MA; Agho KE
    Afr J Prim Health Care Fam Med; 2021 Jun; 13(1):e1-e8. PubMed ID: 34212739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review.
    Onori ME; Ricciardi Tenore C; Urbani A; Minucci A
    Mol Biol Rep; 2021 Mar; 48(3):2973-2978. PubMed ID: 33620659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.
    Gagnon LR; Sadasivan C; Yogasundaram H; Oudit GY
    Curr Heart Fail Rep; 2022 Dec; 19(6):458-466. PubMed ID: 36167917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19.
    Al-Bari AA
    Curr Drug Targets; 2020; 21(16):1703-1721. PubMed ID: 32552642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis.
    Zang Y; Han X; He M; Shi J; Li Y
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):775-782. PubMed ID: 32892293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.
    Rouamba T; Ouédraogo E; Barry H; Yaméogo NV; Sondo A; Boly R; Zoungrana J; Ouédraogo AR; Tahita MC; Poda A; Diendéré AE; Ouedraogo AS; Valea I; Traoré I; Tarnagda Z; Drabo MK; Tinto H;
    Int J Infect Dis; 2022 May; 118():224-229. PubMed ID: 35227869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
    Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
    Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
    Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
    Jung SY; Kim MS; Kim MC; Choi SH; Chung JW; Choi ST
    Clin Microbiol Infect; 2021 Apr; 27(4):611-617. PubMed ID: 33316402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.